In Brief:
Nuchal translucency, pregnancy-associated plasma protein A, total hCG, and inhibin A, in combination, provide first-trimester Down syndrome screening performance similar to that of nuchal translucency, pregnancy-associated plasma protein A, and free β-hCG, in combination.